Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 14, Issue 1, Pages 45-57Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4477
Keywords
-
Funding
- Leona M. and Harry B. Helmsley Charitable Trust Foundation [09PG-T1D027]
- Juvenile Diabetes Research Foundation (JDRF) [17-2007-1063]
- US National Institutes of Health [EB000244, EB000351, DE013023, CA151884]
- JDRF [3-2013-178, 3-2011-310]
- NATIONAL CANCER INSTITUTE [U54CA151884] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000244, R01EB000351, R37EB000244] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013023] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Nanotechnology-based approaches hold substantial potential for improving the care of patients with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices that enable more accurate and patient-friendly real-time tracking of blood glucose levels, and are also providing the basis for glucose-responsive nanoparticles that better mimic the body's physiological needs for insulin. Finally, nanotechnology is being used in non-invasive approaches to insulin delivery and to engineer more effective vaccine, cell and gene therapies for type 1 diabetes. Here, we analyse the current state of these approaches and discuss key issues for their translation to clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available